Piper Sandler Reiterates OW Rating on Corcept Therapeutics (CORT) Following Expert Call
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $131.00 price target on Corcept Therapeutics (NASDAQ: CORT).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
